

**Supplementary Table S2.** Effectiveness of dabrafenib combined with trametinib by the line of therapy in which it was received

	<b>Total<sup>a</sup></b>	<b>First line</b>	<b>≥ Second line</b>
<b>Observed population</b>	<i>N</i> = 271	<i>n</i> = 171	<i>n</i> = 80
Median PFS (95% CI), months	6.8 (6.2–8.1)	8.1 (6.6–10)	5 (3.9–6.3)
Median OS (95% CI), months	18.4 (15.1–NR)	20 (15.5–NR)	15.1 (8.7–NR)
Best overall response, <i>n</i> (%) (95% CI) <sup>b</sup>			
Overall response rate <sup>c</sup>	172 (63.5) (57.4–69.2)	112 (65.5) (57.9–72.6)	48 (60.0) (48.4–70.8)
Complete response	47 (17.3)	28 (16.4)	14 (17.5)
Partial response	125 (46.1)	84 (49.1)	34 (42.5)
Stable disease	33 (12.2)	24 (14.0)	7 (8.8)
Progressive disease	58 (22.4)	28 (16.4)	25 (31.3)
<b>BRAF inhibitor–naïve population</b>	<i>n</i> = 162 <sup>b</sup>	<i>n</i> = 140	<i>n</i> = 22
Median PFS (95% CI), months		8.0 (6.2–9.5)	7.1 (4.6–11.4)
Median OS (95% CI), months		20.0 (14.7–NR)	15.1 (8.7–NR)
Best overall response, <i>n</i> (%) <sup>c</sup>			
Overall response rate <sup>d</sup>		93 (66.4)	16 (72.7)
Complete response		18 (12.9)	3 (13.6)
Partial response		75 (53.6)	13 (59.1)
Stable disease		18 (12.9)	2 (9.1)
Progressive disease		23 (16.4)	4 (18.2)

CI, confidence interval; NR, not reached; OS, overall survival; PFS, progression-free survival.

<sup>a</sup>Data missing for 8 patients in the observed population and 6 patients in the BRAF inhibitor–naïve population.

<sup>b</sup>Data for the total BRAF inhibitor–naïve population can be found in the primary manuscript (Table 2).

<sup>c</sup>Best overall response was unknown for 8 patients, 7 of whom received dabrafenib plus trametinib as first-line therapy.

<sup>d</sup>Complete response + partial response.